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Abstract
Genital herpes simplex virus (HSV) infections are among the most commonly seen 
sexually transmitted infections in the world. Genital herpes is a serious health problem 
because the infection continues through life with remissions and relapses, it causes recur-
ring painful ulcers, and there is no known cure for it. The real prevalence of the genital 
herpes infection is unknown due to asymptomatic cases. The majority of infected indi-
viduals are not aware of the infection due to short duration of symptoms and signs or 
its asymptomatic nature. The clinical presentation of genital herpes shows certain dif-
ferences in terms of the primary attack following the first encounter with the virus and 
recurrent attacks. There is a strong relationship between HSV-2 positivity and human 
immunodeficiency virus (HIV). A serious complication of genital herpes in the mother 
during pregnancy, neonatal herpes, has a mortality risk of 60% if not treated. Antiviral 
therapy is safe and effective, for both episodic treatment and chronic suppression of HSV. 
Epidemiology, clinical presentation, laboratory, and treatment options of genital herpes 
are summarized in this chapter.
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1. Introduction
Genital herpes is a sexually transmitted infection which is seen throughout the world and 
continues through life. It is the most common cause of diseases accompanied by genital ulcer-
ation. Genital herpes is a serious health problem because the infection continues through life 
with remissions and relapses, it causes recurring painful ulcers, the virus transmitted from 
mother to infant causes serious neonatal infections, and there is no known cure for it [1, 2].
Herpes simplex viruses (HSV) are the most common human pathogens causing infections 
in orofacial and genital regions. Genital herpes infection is caused by herpes simplex virus 
1 (HSV-1) and herpes simplex virus 2 (HSV-2). HSV-1 mainly causes infection in oral, facial, 
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and ocular regions and in the central nervous system (CNS) and is transmitted during child-
hood. While in the past genital herpes infections were mostly caused by HSV-2 and orofacial 
infections were mostly caused by HSV-1, HSV-1 is reported to cause genital herpes at an 
increasing rate today, particularly in developed countries [3, 4]. One of the important rea-
sons behind the increase in HSV-1-induced genital herpes cases in developed countries is 
decreased seroprevalence of HSV-1 and the fact that the host has not encountered with the 
virus prior to the onset of sexual activity. Another important reason is suggested to be chang-
ing sexual behaviors among the youth such as oral sex. HSV-2 is usually transmitted through 
sexual contact and causes genital infection. HSV-2 may cause orofacial infections as well, 
which cannot be clinically distinguished from HSV-1-induced infections. However, HSV-2-
induced orofacial infections are very rare [5, 6].
Herpes simplex viruses stay with infected individuals latently for lifetime. Their presentation 
is quite variable depending on the immune condition of the host, site of entry of the virus, and 
whether the disease is primary or secondary [7]. Genital herpes infection has some serious 
results. First of all, HSVs transmitted from the mother to the neonatal cause serious mortal-
ity and morbidity. The second serious risk is the fact that genital herpes infections facilitate 
human immunodeficiency virus (HIV) and play a role in the spread of HIV [8].
2. Epidemiology
Genital HSV infections are among the most commonly seen sexually transmitted infections in 
the world. The real prevalence of the genital herpes infection is unknown due to asymptom-
atic cases. The most common cause of the genital herpes infection is HSV-2, but the number 
of primary genital herpes cases induced by HSV-1 is on the rise. The prevalence of infections 
induced by HSV-1 and HSV-2 varies between countries. While HSV-1 prevalence is about 
60–80% worldwide, its prevalence in developing countries varies between 70 and 100%. HSV-2 
prevalence is reported to vary between 7 and 80% depending on the country, age group, and 
sexual life characteristics. More than 500 million people are estimated to be infected with 
HSV-2 worldwide, which corresponds to 16% of the world population in between the ages of 
15–49. It is also estimated that 20 million new cases occur every year [5, 6, 9].
HSV-1 seroprevalence is associated with age, race, geographical location, and socioeconomic 
status. HSV-2 is associated with age, race, geographical location, socioeconomic status, sexu-
ally transmitted disease history, onset of sexual activity, and number of the sexual partner. 
The most significant determining factor in genital HSV infections is lifetime sexual partner 
count. It was found in a study conducted in the United States that HSV-2 infection and HSV1/
HSV2 co-infection are closely associated with lifetime sexual activity, smoking status, and 
recreational drug use [1, 10].
HSV-1 is typically transmitted during childhood and with non-sexual contact. While HSV-1-
induced genital herpes prevalence varies between geographical regions, almost half of all new 
genital herpes cases are caused by HSV-1 in European countries [12]. HSV-1 seropositivity 
is estimated to be 40–63% in the United States, while HSV-2 seropositivity is estimated to be 
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16–18% [10]. While HSV-1 prevalence was 62% in the United States between 1988 and 1994, 
it dropped to 57.7% between 1999 and 2004. However, HSV-1 seroprevalence was found to 
increase in those who were diagnosed with genital herpes only [3]. Having orofacial HSV-1 
infection during childhood may protect against genital HSV-1 infection in later years and 
silent HSV-2 seroconversion occurs more frequently in individuals with HSV-1 immunity. In 
other words, the transmission rate, duration of disease, and severity of disease are decreased 
in those who have immunity against a HSV type due to cross-immunity. The presence of 
HSV-1 antibodies does not prevent HSV-2 transmission. However, HSV-2 infection may be 
milder or asymptomatic in those with positive HSV-1 antibodies [7, 10, 11].
HSV-2 positivity occurs in adolescence when sexual activity begins and prevalence rate con-
sistently increases toward adult ages. HSV-2 seroprevalence during pregnancy is reported to 
be 7–40% in different parts of the world. It is reported in rates varying between 60 and 95% in 
those infected with HIV and female sex workers [5]. The region with the highest HSV-2 preva-
lence and incidence is sub-Saharan Africa. Prevalence goes as high as 80% for men and over 
the age of 35 for women. HSV-2 seroprevalence is lower in European countries and reports 
vary greatly between countries. In cross-sectional studies for Europe between 1989 and 2000, 
HSV-2 seroprevalence was found to be 4% in Great Britain and Wales, whereas it was found to 
be 24% in Bulgaria. While it was 20–30% in Germany and Switzerland, it went as high as 40% 
in Turkey. The lowest prevalence is reported in Asian countries with 10–30% [12–14].
HSV-2 seroprevalence was found to be 17.2% in the United States in 1999–2000 and 14% 
between 2005 and 2010. It is believed that behaviors reducing sexual risk factors improved 
hygiene and life conditions, improved socioeconomic conditions, and shrinking families 
might have had effective in the decrease in HSV-1 and HSV-2 prevalence [3, 10].
3. Structure of herpes simplex viruses
More than 80 virus types were identified in the herpesvirus family. However, only eight her-
pesviruses cause diseases in humans. Herpesviruses, which are human pathogens, are HSV-1 
(HHV-1), HSV-2 (HHV-2), varicella zoster virus (VZV, HHV-3), Epstein-Barr virus (EBV, 
HHV-4), cytomegalovirus (CMV, HHV-5), human herpesvirus 6 (HHV-6), human herpes-
virus 7 (HHV-7), and human herpesvirus 8 (HHV-8). Herpesviruses, which are the first two 
types of HHVs and responsible for genital herpes infections, are referred to as herpes simplex 
viruses [15].
HSVs are members of the alpha herpesviridea subfamily of the herpesvirus family and have a 
large double-stranded DNA genome. The diameter of the viral nucleocapsid is approximately 
100 nm and the diameter of the virus is approximately 250 nm. The structure of the virus 
consists of a nucleus containing the DNA in the center, an icosahedral capsid surrounding the 
nucleus, a tegument consisting of an amorphous protein layer surrounding the capsid, and 
an envelope surrounding all of these [7, 12]. The envelope is a glycoprotein outer cover and 
is typically derived from the host cell membrane while the DNA-containing capsid passes 
through the nuclear membrane of the host cell. These glycoproteins play an important role 
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during entry into the host cell. Even though DNA sequences of HSV-1 and HSV-2 are very 
similar, they have different antigenic structures due to differences in envelope proteins [16].
HSVs are required to attach to at least three different cell surface receptors to start the infec-
tion. As a result of this attachment, the plasma membrane and the virus envelope join and 
the virus enters into the cell as a result. The viral envelope contains at least 12 different gly-
coproteins involved in the virus’ entry into and exit from the cell (gB, gC, gD, gE, gH, gI, gK, 
gL, and gM) [17]. Five different envelope proteins are involved in the virus entry process. 
Surface glycoproteins of HSVs mediate attachment to and entry into host cell surface and also 
stimulate the host’s immune system [12]. Heparan sulfate proteoglycans (HSPGs) on the cell 
surface are attachment regions for HSVs. gB and gC bind HSPGs and are necessary for attach-
ment. Fırst, gD binds cell surface receptor and starts changes which allow for membrane 
fusion of other glycoproteins. Nectin-1 is a cell adhesion molecule, which gD binds and also 
the main HSV receptor found in epithelial cells and neurons [12, 17, 18].
The viral genome is required to pass through the cell surface and cytoplasm and reach the 
nucleus for the replication of the virus. Entry of the virus into nucleus occurs in three stages. 
The first stage is the absorption of the virion to the cell surface, the second stage is passing 
through nuclear pores after passing through the plasma membrane, and the third stage is 
the introduction of the viral DNA from the capsid [16]. HSVs mostly use their own DNA 
synthesis mechanisms for genome replication; however, they are dependent on the host’s 
RNA polymerase II for transcription of viral genes. Viral DNA synthesize requires at least 
seven viral proteins. At least six viral proteins allow for robust expression of viral genes and 
mobilize cellular proteins for effective synthesis of the viral DNA and proteins. Other viral 
proteins, mainly thymidine kinase (TK), ribonucleotide reductase, dUTPase, and uracyl DNA 
glycosylase, control viral nucleic acid metabolism. These proteins are potential targets of anti-
viral treatment [12].
4. Pathophysiology
Host’s immune system is the most important factor which determines the transmission, sever-
ity, and frequency of recurrence of the infection. Humoral and cellular immune systems limit 
the spread of the virus in immune-competent individuals. In experiments with both humans 
and rats, CD4+ and CD8+ T lymphocytes, macrophages, natural killer cells, and inflamma-
tory cytokines such as interferon-γ were shown to be involved in protection against HSVs 
[5, 19]. While individuals with mild cellular immune deficiency experience frequent recur-
rences and slower resolution, individuals with severe immune deficiency are at a higher risk 
of disseminated, treatment-resistant, and chronic disease. More frequent and severe recur-
rent herpes infections in acquired immunodeficiency syndrome (AIDS) patients indicate the 
importance of cellular immunity, CD4+ T cells in particular [9]. Humoral immune system, on 
the other hand, does not affect disease severity. However, it is involved in reduction of virus 
titer in inoculation region and neural tissues during primary infection [5, 19]. Another cell 
that is primarily affected in genital herpes and involved in immune response against HSV-2 
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is keratinocytes. Keratinocytes infected with HSV-2 show up-regulation of antiviral cytokines 
such as interferon alpha, beta, tumor necrosis factor-alpha (TNF-α), colony-stimulating fac-
tors, growth factors, defensins, selectins, lymphocyte function-associated antigens, and Toll-
like receptors [20].
Genital HSV infections are more common in women compared to men. Studies show that 
women are more vulnerable to transmission than men. This vulnerability is believed to arise 
from anatomic characteristics of women, the structure of the genital epithelium, longer expo-
sure to inoculum, and a higher rate of viral reactivation among men than women. When it 
comes to sexual transmission, the risk of transmission from man to woman is higher than the 
risk of transmission from woman to man. The virus is easily deactivated with water, soap, and 
drying and transmission through objects is not likely [21].
The virus, which enters into the body through skin or mucosa, starts the cytolytic replication 
within epithelial cells. In this period, virions within epithelial cells are observed histologically 
as intranuclear inclusions. Cells turn into multinucleated giant cells due to cytolytic proper-
ties of HSVs. Epithelial cells break up due to cell damage, and the space between separated 
cells is filled with liquid. Resulting blisters contain cellular debris, inflammatory cells, and 
virion products [5].
HSVs are neurotropic human pathogens. Following the replication in epithelial cells, the virus 
is absorbed by sensory neurons that innervate these tissues. The virus travels through neu-
ron body and to neural ganglia via retrograde microtubule-associated transport and remains 
latently in neural ganglia without leading to cell death in neurons. It is unknown why and 
how HSVs remain latently. However, after a single lytic infection, the virus gains ability to 
protect against host’s defense system. The latent virus genome is kept within sensory neurons 
in a balanced manner and all viral lytic genes are suppressed. The virus may reactivate to con-
tinue its replication due to various triggering factors and reaches epithelial cells via antero-
grade transport. Infected cells do not spread virus for the duration of latent infection and 
disease symptoms are not observed in the host. Trigeminal and sacral ganglia are the regions 
where HSV-1 and HSV-2 viruses most frequently remain latent. Recurrent genital herpes 
infection usually occurs as a result of reactivation of the virus remaining latent in sacral root 
ganglia [9, 17, 22]. Many factors such as traumas, inflammatory diseases, ultraviolet, men-
struation, immune suppression, fatigue, and psychological stress may lead to reactivation 
of the latent virus. Following the virus reactivation, the virus reaches mucosa and skin once 
more from dorsal root ganglia through peripheral nerves. The infection maybe symptomatic 
or asymptomatic and seroconversion of type-specific antibodies takes 4–6 weeks [11].
4.1. HSV/HIV relationship
There is a strong relationship between HSV-2 positivity and HIV. The risk of HIV transmission 
is three times higher in women and men infected with HSV-2 [23, 24]. Among HIV-positive 
patients in UK, HSV-1 seroprevalence was found to be 90%, HSV-2 seroprevalence was found 
to be 67%, and HSV-1 and HSV-2 co-incidence was found to be 64% [25]. Worldwide, more 
than half of individuals infected with HIV have HSV-2 infection. Genital herpes lesions are 
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suggested to facilitate HIV acquisition due to disruptions in physical barriers of skin and 
mucosa. Another facilitating factor may be HIVs reaching a high number of CD4+ cells due 
to increased cellular inflammatory response. HSV-2 infection is believed to have played a 
facilitating role in HIV endemic in sub-Saharan Africa. HSV suppression treatment has not 
been shown to prevent HIV transmission [13, 20, 26]. In addition, HSV-2 infection is sug-
gested to accelerate HIV disease and increase viral load. HSV treatment with acyclovir has 
been shown to slow down HIV progression in individuals co-infected with HIV and HSV-2. 
Some authors recommend that HIV-infected patients are checked for HSV-2 and co-infected 
individuals receive suppression treatment for HSV-2. However, this subject has not been fully 
illuminated. Although it is known that HSV-2 positivity facilitates HIV transmission, there is 
no evidence showing that it accelerates AIDS progression. On the other hand, HIV viral load 
has been reported to increase HSV-2 activity [26].
5. Clinic
Genital herpes lesions are formed by both HSV-1 and HSV-2 viruses. Severity of clinical signs 
varies significantly. Since the majority of individuals infected with HSV do not realize a clini-
cal symptom, they are not diagnosed with genital herpes. Therefore, they continue to spread 
the virus without knowing that they are infected. While mild and moderate symptoms and 
signs are observed in some patients, the first attack may be as severe as to require hospitaliza-
tion in others. HSV-1-induced genital herpes may be milder and recur less frequently than the 
infection induced by HSV-2. The incubation period after the transmission of the virus is not 
known with certainty. The primary infection occurs 2–12 days (4 days on average) after sexual 
contact. In one study, based on the data obtained from patients who were aware of having the 
primary attack, the time between the sexual contact and the primary attack may vary from 1 to 
49 days and thus it is suggested that the incubation period may be longer than expected [27].
The majority of infected individuals are not aware of the infection due to short duration of 
symptoms and signs or its asymptomatic nature. For this reason, genital herpes should be 
considered in patients with nonspecific genital symptoms. The clinical presentation of genital 
herpes shows certain differences in terms of the primary attack following the first encounter 
with the virus and recurrent attacks [28].
5.1. Primary genital herpes
Although episodes in most primary genital herpes cases are asymptomatic or atypical, clini-
cal signs are similar for both HSV-1 and HSV-2 in terms of the classical symptomatic first 
episode. In the prodromal period, patients may have headache, fever, anorexia, malaise, and 
painful inguinal and femoral lymphadenopathy. Following the prodromal period which lasts 
for 2–24 h, patients experience localized or regional pain and tingling and burning sensations. 
Constitutional symptoms are present in 80% of patients [11, 27]. Primary lesions begin about 
4–7 days after sexual contact on labia minora, introitus, and urethral meatus in women and 
on penis shaft and glans in men as painful, erythematous, clustering vesicles, and papules in 
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varying sizes. Painful and inflammatory vulvar edema is present in women. Other than the 
genital region, lesions may be seen on perineum and hips. Proctitis is one of the important ini-
tial symptoms in homosexual men. Irregular erosions and ulcers are formed due to ruptured 
vesicles. Since circulating antibodies are not on a sufficient level, autoinoculation may occur 
in other anatomical regions during or after the primary genital infection in particular. Lesions 
are crusted and heal without scarring after 2–3 weeks. In this period, patients may spread 
the virus for approximately 12 days. Atypical course may be present in women with cervical 
lesions, which are usually overlooked, and it is more difficult to make a diagnosis. The moist 
property of the genital region in women may lead to more severe clinical signs. Dysuria is 
also more common in women. Autonomic dysfunction and aseptic meningitis, which lead to 
urinary retention, are complications seen in this period. These lesions may sometimes occur 
without said complications. In primary genital herpes infections, aseptic meningitis is seen 
in 30% of women and 10% of men [7, 11]. The most common and unsettling symptom dur-
ing the first episode is reported to be pain in women. In men, on the other hand, lesions are 
reported to be the most common and unsettling symptom. Surveys made with patients show 
that female patients experience more work force loss during the first genital herpes attack 
compared to male patients [29].
5.2. Recurrent genital herpes
The virus remaining latent in sensory neural ganglia following the primary genital herpes 
reactivates and causes recurrent infections. Recurrent lesions occur more commonly in men. 
Recurrence is observed in 70–90% of HSV-2-positive individuals and in 20–50% of HSV-1-
positive individuals who have had a symptomatic primary genital infection [5]. Recurrences 
are six times more frequent in HSV-2 infections compared to HSV-1 infections [1]. One to two 
days prior to recurrent lesions, prodromal signs such as itching, tingling, paresthesia, and 
pain in lumbosacral dermatomes are observed. Recurrent genital herpes lesions involve less 
grouped lesions compared to primary genital herpes and tend to be unilateral (Figure 1). It 
Figure 1. Painful grouped vesicles are seen. By the courtesy of Dr. Zekayi Kutlubay.
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is usually not accompanied by systemic symptoms. Lesions are painful; however, the pain is 
milder compared to primary infection. Lesions usually heal within 7–8 days and viral spread 
lasts shorter and its concentration is lower. Recurrences may occur on thighs, lower abdomen, 
hips, and genital organs. Fissures, erythematous patches, excoriations, and linear ulcerations 
may be seen as atypical lesions [1, 11, 30]. Recurrent infections become sparse in time. That 
being said, recurrences have been reported in 25% of patients in the fourth year of infection [5].
5.3. Asymptomatic genital viral shedding
Genital herpes infections are characterized by lifelong viral shedding after the first genital 
herpes attack. Viral shedding in individuals infected with genital herpes continues with 
both lesional and asymptomatic periods. Fifty to ninety percent of transmissions occur from 
infected individuals who are not aware of their infections during the asymptomatic viral 
shedding period. Only 25% of HSV-2-seropositive individuals have genital herpes history. 
The majority of infected individuals either carries the infection asymptomatically or is not 
aware of symptoms [1, 2]. The period with the highest risk of transmission is the active dis-
ease period which involves visible lesions. Shedding continues for 1 week after symptom-
atic attacks. However, viral reactivation is characterized by asymptomatic viral shedding in 
most patients. The asymptomatic shedding property of the virus is the most significant reason 
behind its spread. Viral shedding is very common in HSV-2-seropositive patients, whereas it 
is less common in asymptomatic HSV-1 patients. The cell shredding rate is 3–5% in cell cul-
tures obtained from women infected with genital HSV-2 in asymptomatic period; however, 
this rate goes up to 28% when wipe samples are examined using the polymerase chain reac-
tion (PCR) method.
Studies show that the highest shedding rates are seen within the first year following the onset 
of the infection. In a study involving 377 adults with genital herpes, viral shedding was exam-
ined by applying the PCR method to anogenital swab and found to be 33.6% within the first 
year after the first attack, 20.6% between 1 and 9 years, and 16.7% over 10 years. Subclinical 
viral shedding was shown to be similar in both men and women.
5.4. Neonatal herpes
A rare yet serious complication of genital herpes in the mother during pregnancy, neonatal 
herpes, has a mortality risk of 60% if not treated. It may lead to mortality and permanent 
sequels in 30% of cases in spite of antiviral treatment. Neonatal herpes is estimated to be 
about 10 in 100,000 live births worldwide. This corresponds to approximately 14,000 neonatal 
herpes (4000 HSV-1 and 10,000 HSV-2) cases every year. The highest number of neonatal her-
pes cases belongs to Africa due to high HSV-2 positivity rate among women and high birth 
rate. HSV-1 infections cause more neonatal herpes cases than HSV-2 infections in the United 
States, Europe, and the West of the Pacific [31].
Transmission from the mother to the infant mostly (85%) occurs during vaginal birth due to viral 
shedding. Intrauterine (5%) and postnatal (10%) transmission cases are less common [2, 8]. Its 
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clinical manifestation involves eye, mouth, and skin infection, central nervous system disease, 
or disseminated disease which starts within the first 28 days of life. Eye, mouth, and skin infec-
tion is present in 45% of cases and characterized by vesicular lesions without CNS involvement 
or disseminated disease. CNS disease is observed in about 30% of cases and characterized by 
lethargy, feeding difficulty, and seizures. CNS disease may be accompanied by skin lesions. The 
mortality is 6% and permanent moderate and severe neurological damage is 50% with intra-
venous (IV) acyclovir treatment. Disseminated disease consists of the remaining 25% of cases 
and presents multiple organ involvement with clinical sepsis. The mortality is 30% in spite of 
acyclovir treatment [20].
6. Laboratory
Although genital herpes can be diagnosed via patient history and examination, herpes diag-
nosis may not always be easy. There may be atypical localizations such as hip and thigh or 
atypical presentations such as vulvar/penile/perianal fissures, recurrent erythema, recurrent 
pain, cystitis, urethritis, and genital discharge without lesions. On the other hand, various 
diseases causing ulcers in the genital region such as Behcet’s disease, Crohn’s disease, other 
sexually transmitted diseases, and fixed drug eruption may mimic herpes. In such cases, the 
patient may be subjected to unnecessary antiviral treatments and experience negative social 
and psychosocial effects due to the diagnosis. For a thorough infection management, the clini-
cal diagnosis must be supported with laboratory confirmation. Supporting the diagnosis is 
also important for detection of possible cases, further consulting services, and prevention of 
serious complications such as neonatal herpes [32–34].
6.1. Virus detection and typing
It refers to displaying the viral genome on the skin or mucosal membrane. The best test sample 
is vesicle content. Samples must be sent to the laboratory in saline or virus transport medium 
[30]. Virus detection methods are mainly divided into four groups: cell culture, molecular 
methods (nucleic acid amplification tests (NAATs)), direct viral antigen detection, and cyto-
logical examinations [34]. The most commonly preferred methods are cell culture and PCR, 
which is a NAAT method. It is possible to distinguish between HSV-1 and HSV-2 using these 
two methods. It is absolutely necessary to distinguish between HSV-1 and HSV-2 in newly 
diagnosed genital herpes cases [35]. Because viral shedding is intermittent, the fact that no 
infected cell is detected does not mean that the HSV infection is not present [36].
Cell culture has lost its previous significance since it has low sensitivity in cases of healing 
lesions and ulcerative lesions and requires more time compared to PCR. NAAT methods such 
as PCR are accepted as the reference test by many centers due to their high sensitivity [30, 34, 
36, 37]. Other advantages of NAAT methods include reproducibility, speed, and labor efficiency 
[38]. Direct viral antigen detection is a good alternative since it results in a matter of hours and 
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is a commercially accessible method. However, it has certain disadvantages such as low speci-
ficity and sensitivity values and inability to distinguish types. Cytological methods based on 
detection of cellular changes such as Tzanck are not recommended due to lack of specificity and 
sensitivity. Similarly, these methods do not allow for distinguishing types as well [34].
6.2. Serology
Immunoglobulin M (IgM) antibodies can be detected in blood 7–10 days after encountering 
the infectious agent. They remain detectable for about 1–2 weeks, while they remain positive 
for about 6 weeks in some individuals. They become positive again within a short time frame 
in recurrent infections [39]. Detection of IgG antibodies may require 2 weeks to 3 months fol-
lowing the transmission of the virus and they remain positive for lifetime [5]. Although IgM 
detection in IgG negativity during the window period in the first infection in particular may be 
important for primary infection diagnosis, it is not recommended for routine practice [34, 40].
HSV-1 IgG antibodies do not allow for distinguishing between genital and oropharyngeal 
infections, HSV-2 IgG antibodies can be used to confirm genital herpes infection diagno-
sis. For this reason, detection of type-specific HSV IgG antibodies, especially HSV-2, is very 
important to use type-specific serological tests for an accurate and effective genital herpes 
management [6, 34].
Detection of type-specific HSV IgG antibodies is a rapid, effective, and reliable method in 
infection diagnosis. Although it does not provide information related to infection time, it is 
possible to support primary infection diagnosis in individuals who are believed to have the 
first genital herpes attack. When used together with direct virus detection methods, primary 
infection diagnosis is possible with observing the initially negative IgG value, which is spe-
cific to HSV type, becoming positive in repeated PCR tests. Serology is also effective in detec-
tion of asymptomatic HSV-2 carries and possible viral shedders [30]. Especially patients with 
negative direct virus detection tests, yet recurrent or atypical genital symptoms and partners of indi-
viduals diagnosed with genital herpes are suitable indications. If the partner is HSV-2-negative, 
it is important to detect the infection to take protective measures. It is also important to know 
the HSV serology in case of pregnancy to protect against neonatal herpes, which is a serious 
condition, and take necessary measures. Moreover, HSV-2 infection increases the risk of HIV 
transmission independently and leads to disease progression in HIV-seropositive patients. 
Therefore, HSV serology should be explored especially for individuals with multiple partners 
and/or HIV-seropositive individuals to control sexually transmitted diseases and manage HIV. 
HSV serology has no indication in general population [34]. Table 1 shows how to interpret 
laboratory findings in detail.
Type-specific serological tests are commercially available and the enzyme-linked immuno-
sorbent assay (ELISA) method is widely used. They depend on detection of HSV-specific gly-
coprotein G1 or C1 (HSV-1) and glycoprotein G2 (HSV-2) as antigen [36]. These tests have a 
sensitivity of 97–100% and a specificity of 94–98% [5, 41]. Although there are multiple tests 
used for confirmation, the Western Blot test is accepted as the gold standard and can be found 
in only a number of reference centers [34].
Fundamentals of Sexually Transmitted Infections58
7. Treatment
Systemic antiviral use is the essential point of genital herpes treatment. Studies have shown 
that systemic antiviral treatment limits the severity and duration of the genital herpes attack 
[42, 43]. The important point to keep in mind is that antiviral treatment does not eliminate 
latent infection and does not affect posttreatment recurrence risk and severity [36].
In treatment of HSV-1- and HSV-2-induced genital herpes, it is recommended to use acyclo-
vir, valacyclovir, and famciclovir as the standard primary care [30, 36]. These are nucleoside 
analogs which inhibit herpesvirus DNA polymerase specifically. While acyclovir is available 
in IV and oral forms, valacyclovir and famciclovir are available in oral form only. These three 
agents have similar activities in terms of reducing disease severity, duration, and recurrence 
[44]. Acyclovir is the prototype drug since it is the first molecule used. It is safe and has high 
HSV-1 detection 
by direct method
HSV-2 detection 
by direct method
HSV-1-specific 
IgG
HSV-2-specific 
IgG
Interpretation
First assessment 
of genital lesions
Positive Negative Negative Positive or 
negative
Acute HSV-1 
infection. Repeat 
HSV-1-specific 
serology within 
15–30 days
Negative Positive Positive or 
negative
Negative Acute HSV-2 
infection. Repeat 
HSV-2-specific 
serology within 
15–30 days
Recurrent genital 
lesions
Positive Negative Positive Positive or 
negative
Recurrent HSV-1 
infection
Negative Positive Positive or 
negative
Positive Recurrent HSV-2 
infection
Negative Negative Negative Positive Possible recurrent 
HSV-2 infection. 
Other potential 
causes of genital 
ulcerative 
disease should be 
considered
Negative Negative Positive Negative Possible recurrent 
HSV-1 infection. 
Other potential 
causes of genital 
ulcerative 
disease should be 
considered
Table 1. Virological and serological approach to genital HSV infection.
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tolerability. Gastrointestinal system complaints, eruption, and temporary neurotoxic effects 
are possible. Nephrotoxicity may develop in insufficiently hydrated cases. Concurrent neph-
rotoxic drug use should be avoided, liver and kidney functions should be followed closely, 
and the dose should be adjusted in case of renal failure [45]. Valacyclovir is the prodrug form 
of acyclovir. Valacyclovir is converted to acyclovir by hepatic valacyclovir hydrolase. It has 
higher oral bioavailability. Its use is not licensed for children, adolescents, and pregnant 
women. Its side effect profile is similar to that of acyclovir. Famciclovir is the prodrug form 
of penciclovir, which is only available in topical form. It has a quite high oral bioavailability. 
Similar to valacyclovir, its use is not licensed for children, adolescents, and pregnant women. 
Possible side effects include headache, nausea, and diarrhea [30].
The effect of topical agents is weaker than systemic agents and they do not contribute to 
combined treatment. They are not recommended for use in case of genital herpes since they 
lead to an increase in resistance. Intravenous treatment should be considered only when oral 
agents cannot be tolerated and in complicated cases [35]. Washing with serum physiologic 
and using analgesic and topical anesthetic agents are additional approaches which may be 
beneficial.
7.1. Primary genital herpes
Primary infections are usually more severe and longer compared to recurrent attacks. 
Therefore, guides recommend systemic antiviral use in all primary genital herpes cases. It is 
recommended that treatment is started within the first 5 days. If new lesion formation contin-
ues, treatment should be started in cases older than 5 days as well. The patient should be fol-
lowed up closely in terms of systemic symptoms, complications, and new lesion formation. In 
such cases, it may be necessary to prolong the standard treatment [35, 36, 46]. Table 2 shows 
recommended doses in detail.
7.2. Recurrent genital herpes
Recurrent genital herpes attacks are usually self-limiting and not so irritating compared to 
the first attack. However, attacks may sometimes be very frequent (four to six times a year 
or more) and severe and reduced the individual’s life quality. In such cases, two different 
regimens are used: the suppressive treatment and the intermittent treatment. Patient com-
pliance and cost should be considered when choosing a treatment regimen. Table 2 shows 
recommended doses in detail. Acyclovir is low in cost compared to the other two agents. 
Intermittent treatment seems to be more advantageous than suppressive treatment in terms 
of both patient compliance and cost. Although studies show that both treatment regimens 
are effective and safe, suppressive treatment is more effective [47]. Thus, the World Health 
Organization (WHO) recommends suppressive treatment at first and to stop the treatment 
after 1 year to reassess recurrence frequency [46]. Since the patient usually experiences an 
attack after stopping the treatment, it is recommended to wait at least for the second attack. 
The treatment may be restarted after reassessment for patients who have unacceptable attack 
frequency and symptoms [35].
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7.3. Management of complications
Complications such as urinary retention, meningoencephalitis, disseminated disease, pneu-
monia, and hepatitis, which are usually observed during the first attack and in immunosup-
pressive individuals, should be treated by hospitalizing the patient. The patient should be 
administered acyclovir 5–10 mg/kg IV every 8 h for 2–7 days or until clinical recovery is 
observed. The initial intervention should be followed up with oral antiviral treatment and the 
process should be completed in a total of 10 days. The treatment should be 21 days in case of 
HSV encephalitis [36].
First episode for genital herpes (adult, pregnant, 
immunosuppressive patients)
Oral dosesa
Acyclovirb 400 mg three times a day for 5–10 days or
200 mg five times a day for 5–10 days
Valacyclovir 500–1000 mg twice a day for 5–10 days
Famciclovir 250 mg three times a day for 5–10 days
Suppressive therapy for recurrent genital herpes
Acyclovirb 400 mg twice a dayd
200 mg four times dailyc
Valacyclovir 500 mg once a day or
1 g once a dayd
Famciclovir 250 mg twice a day
500 mg twice a dayd
Episodic therapy for recurrent genital herpes
Acyclovirb 400 mg three times a day for 5 daysd or
800 mg twice a day for 5 days or
800 mg three times a day for 2 days
Valacyclovir 500 mg twice a day for 3 days or
1 g once a day for 5 daysd
Famciclovir 125–250 mg twice a day for 5 days or
1 g twice a day for 1 day or
500 mg for 1 dose followed by 250 mg twice a day for 2 
days
500 mg twice a day for 5 daysd
aFirst episode oral doses vary according to guidelines.
bRecommended as the first choice in the WHO STI guideline.
cHas a usage difficulty although it is found more efficient than the usage of 400 mg twice a day.
dThe recommended dose for the people HIV+ and have more than 10 episodes a year.
Table 2. Treatment of genital herpes.
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7.4. Special cases
7.4.1. HSV management in pregnancy
Neonatal herpes during pregnancy is a serious health problem with high mortality and mor-
bidity. Herpes must be managed carefully during pregnancy to minimize the risk of transmis-
sion to fetus. Primary/recurrent character of the maternal infection, presence of transplacental 
neutralizing antibodies, presence of premature rupture of membranes, fetal scalp electrode 
use, and labor method are factors which affect transmission [48]. Maximum risk occurs with 
the primary infection acquired during the third trimester.
7.4.1.1. Primary attack management
Treatment should not be delayed in case of primary attack. Oral acyclovir administration in 
standard dose (400 mg/three times/day) is recommended as primary care. If the maternal 
infection is disseminated, IV use should be considered [49]. Although all three agents are 
accepted to be safe, valacyclovir and famciclovir are not recommended for primary care due 
to insufficient data [49–51]. If the attack occurs during the first or the second trimester, sup-
pressive treatment with acyclovir may be started again from the 36th week until labor [52, 53]. 
If the attack occurs during the third trimester, acyclovir administration should be continued 
until labor. Detection of type-specific HSV antibodies is recommended for pregnant women 
who apply due to primary attack during the third trimester. Detection of the same antibody 
type with the type isolated on genital swab usually indicates recurrent attack rather than 
primary attack. There is no elective C-section indication in such cases. Otherwise, if there is 
also any doubt, attacks in the third trimester should be treated as primary attack and elective 
C-section should be used [49].
7.4.1.2. Recurrent attack management
Existing protective antibodies of the pregnant woman with recurrent attack protect the fetus 
against transplacental transmission. Thus, neonatal herpes is not common in recurrent herpes 
cases. While antiviral treatment is not recommended for recurrent attacks before the 36th 
week, standard treatment may be considered in severe cases [54, 55]. It has been shown that 
suppressive treatment with acyclovir from the 36th week until labor reduces viral shedding, 
clinical herpes lesions, and requirement for C-section [56]. Vaginal birth should be preferred 
if there is no other obstetric contraindication. Even though vaginal birth is recommended in 
case of lesion presence during birth, the final decision should be made by the mother due to 
low neonatal herpes risk [49].
7.4.2. HSV management in HIV-positive patients
HSV is a condition that requires careful assessment in HIV+ patients. Similar to immuno-
competent individuals, reactivation is subclinical in most cases [57]. However, the form of 
reactivation is closely related with the rate of immunosuppression and ulcerate, necrotic, 
painful, massive, multiple, and atypical lesions may be observed especially in patients with 
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low CD4+ cell count [58]. Resistance is a high possibility in HIV+ patients. Antiviral treat-
ment has been shown to be effective in HIV+ patients as well [59, 60]. However, antiviral 
treatment has not been found to be effective in preventing the transmission of HIV or HSV to 
the possible partner [61, 62]. Table 2 shows doses for HIV+ patients.
7.5. Cases of resistance
Drug resistance should always be considered in cases where lesions become chronic or new 
attacks occur under antiviral treatment. Development of drug resistance against acyclovir and 
derivatives has been increasing due to high prevalence of herpes and frequent and prolonged 
use of accessible agents. There is a vast difference between immunocompetent and immuno-
suppressive cases in terms of drug resistance. Immunocompetent individuals rarely develop 
drug resistance, while drug resistance rates up to 36% have been reported for immunosup-
pressive cases in the literature. In a clinical study on patients with genital herpes, the acyclovir 
resistance rate has been found to be 0.18% for HIV-negative cases and 5.3% for HIV-positive 
cases [63–65].
Acyclovir resistance occurs through HSV thymidine kinase gene mutations. Phenotypically, 
it is observed as loss in TK activity, reduced TK production, or reduced affinity for substrate 
[66]. Acyclovir resistance is accompanied by cross-resistance against other nucleoside ana-
logs such as valacyclovir, famciclovir, ganciclovir, and penciclovir since they share the same 
mechanism. While treatment with high doses of acyclovir and analogs is possible in cases of 
partial resistance, other treatment methods, which do not depend on TK, should be consid-
ered in cases of complete resistance [35, 67]. An oral agent other than acyclovir and analogs is 
not available. Foscarnet (40–80 mg/kg IV every 8 h) administration is the first choice after high 
doses of acyclovir in case of non-response to nucleoside analogs. Non-response to foscarnet 
is also possible, albeit rare. In such cases, IV cidofovir administration (5 mg/kg/week) may be 
considered [68]. Topical imiquimod is a good alternative in cases where IV treatment is not 
possible [69–71]. Although it is effective in resistant cases, topical cidofovir is disadvantaged 
due to lack of a commercially available preparation [72].
8. Protection from transmission
The first and most important approach is to inform asymptomatic partners and detection of 
possible asymptomatic carriers by assessing type-specific HSV-2 antibodies. Although it is 
not possible to fully protect HSV-2-seronegative partners from transmission, it is possible 
to minimize the risk. The primary reason behind sexual transmission is asymptomatic viral 
shedding. Both HSV-1- and HSV-2-induced genital herpes cases may involve asymptom-
atic viral shedding. Viral shedding is more common in individuals with frequent and severe 
attacks in particular. The first step to protection is to encourage condom use. It has been 
shown to have quite high effectiveness in regular use and higher effectiveness in transmission 
from man to woman [73]. Sexual intercourse should be avoided during active attack peri-
ods. Asymptomatic viral shedding responsible for transmission can be suppressed with all 
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systemic antiviral treatments [74, 75]. A reverse transcriptase inhibitor analog also approved 
for HIV, gel form of tenofovir, has been shown to protect HSV-seronegative women against 
transmission when used 12 h prior to intercourse [76]. SPL7013 gel (VivaGel®) is a microbicide 
developed to protect against HIV and HSV. It has been found to have strong antiviral activity 
when used 3 h before intercourse [77].
Efforts to develop a vaccine for HSV-1 and HSV-2 are among the priorities of WHO. Although 
there is no licensed HSV vaccine available as of now, there are numerous vaccines at clinical 
and preclinical study stages. Studies have gained pace, thanks to a better understanding of 
immune response against HSV [78]. Vaccines generally have two different purposes: reduc-
tion of disease activity and viral shedding (therapeutic) and prevention of infection occurrence 
(prophylactic). The most common HSV vaccines used in human clinical studies are glycopro-
tein subunit (gp D2) vaccines. A HSV subunit vaccine, HerpeVac, is a prophylactic vaccine and 
has the most intensive clinical study. In a study on HSV-1- and HSV-2-seronegative women, 
it has been found that the vaccine provides 58% protection against HSV-1; however, it has 
no protective effect against HSV-2 [79]. Clinical phase II studies of four prospective vaccines 
with therapeutic indications still continue today. First results of studies on GEN-003, a gD2/
ICP4 protein subunit vaccine with Matrix M adjuvant, indicate that the vaccine reduces viral 
shedding by about 50% [80]. HerpV, a peptide vaccine with 32 peptides complexed with heat 
shock proteins and Q-21 adjuvant, is another therapeutic vaccine and reduces viral shedding 
by 15%. The other two vaccines (codon-optimized polynucleotide vaccine and VCL-HB01/
HM01) are DNA vaccines and research results are awaited for these vaccines. Phase I studies 
for HSV529, a replication-defective HSV-2 vaccine, have started with both therapeutic and 
prophylactic indications [81].
9. Consultancy
It is very important to inform herpes-seropositive individuals and their partners accurately 
and completely and eliminate their concerns. Because it is possible to improve their life qual-
ity through the right consultancy, transmission can be minimized and cases such as neonatal 
herpes may be prevented. It is not an accurate and complete approach to provide medical 
services only. Patients should be provided consultancy in the first visit. A healthy consultancy 
and information should involve the following:
• General: HSV is not a race- or gender-specific infection. While having multiple partners 
increases the risk, it may be seen in monogamous individuals as well. Transmission is pos-
sible without clinical lesions and symptoms (asymptomatic viral shedding). Recurrences 
are likely to happen.
• Treatment: It is possible to reduce lesion duration and severity, attack frequency, asymp-
tomatic viral shedding, and negative psychological effects on the patient using antiviral 
systemic treatment [44, 82].
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• Protection: It is important that current and future partners are informed by the HSV-pos-
itive individual. Partner status should be determined by serology and HSV-negative part-
ners should be informed about possible measures. Intercourse should be avoided during 
active lesion presence and transmission risk should be minimized by condom use. HSV+ 
women should be informed about the neonatal herpes risk, and obstetricians and gyne-
cologists should be urged to inform patients during pregnancy. In addition, it should be 
mentioned that HIV transmission risk is increased in HSV-2-positive individuals.
• Psychology: Mental health of individuals may be negatively affected upon diagnosis due 
to shame, guilt, fear, and despair. Words such as “chronic, incurable, attack” should be 
avoided during the visit to prevent increased concern. The patient may not understand 
what is told during the first visit due to the shock caused by the diagnosis. For this reason, 
the patient should be followed up in future visits. The individual may overcome the dif-
ficulty by sharing experiences with or learning from others with the same infection. There 
are various support platforms which can be used for this purpose and the individual may 
be referred to such platforms [35, 36, 83].
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